Scott Centea - Jul 20, 2022 Form 4 Insider Report for ANGIODYNAMICS INC (ANGO)

Role: SVP/GM, VIT
Signature: /s/ Richard C. Rosenzweig, Attorney in Fact
Stock symbol: ANGO
Transactions as of: Jul 20, 2022
Transactions value $: $0
Form type: 4
Date filed: 7/22/2022, 06:28 PM
Previous filing: Nov 5, 2021
Next filing: Jul 18, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ANGO	Common Stock	Award	$0	+3.71K	+8.18%	$0.00	49K	Jul 20, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ANGO	Performance Right	Award	$0	+7.41K		$0.00	7.41K	Jul 20, 2022	Common Stock	7.41K		Direct	F2
transaction	ANGO	Non- Qualified Stock Option (right to buy)	Award	$0	+8.68K		$0.00	8.68K	Jul 20, 2022	Common Stock	8.68K	$21.53	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The acquisition of 3,705 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 3,705 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 20, 2023, such that 25% of the restricted stock units will vest on each of July 20, 2023, 2024, 2025 and 2026.
F2	Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.
F3	These stock options vest in four equal annual installments beginning on July 20, 2023, such that 25% of the options will vest on each of July 20, 2023, 2024, 2025 and 2026.